Answers are grounded in this paper and cite their sources.
Observational study reveals diagnostic accuracy of plasma phosphoethanolamine in depressive disorder, highlighting its utility as a psychiatric biomarker.
OBJECTIVES: Plasma phosphoethanolamine (PEA) has been proposed as a potential biomarker for depressive disorder. To further assess its diagnostic utility and relevance across psychiatric conditions, we conducted a larger observational study in a psychiatric primary care setting. METHODS: Between 2013 and 2020, 576 patients underwent DSM-5-based psychiatric assessments. Plasma PEA levels were measured in 295 patients with depressive disorders, 264 with other psychiatric disorders, and 17 with physical illnesses. RESULTS: PEA demonstrated moderate or high diagnostic accuracy for depressive disorder (AUC = 0.81, 95% CI: 0.78-0.85). Lower PEA levels were significantly associated with depression (OR = 16.30, p < 0.001). CONCLUSIONS: These findings suggest that plasma PEA concentration may serve as a useful biomarker for depressive disorder. Further studies are warranted to explore its potential relationship with white matter pathology in psychiatric conditions.
No takes yet. Share an insight, caveat, or question.
Kawamura et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: